

**Supplementary material.**

**Supplementary table 1.**

Inducible urticaria according to challenge test	(+) Anti-TPO IgE (n 43)	Group 1 (n 18)	Group 2 (n 12)	Group 3 (n 13)	p
Patients with any inducible urticaria	10 (23.2%)	5	3	2	0.14
<i>Dermographism</i>	7 (16.2%)	4	2	1	0.13
<i>Pressure</i>	1 (2.3%)	1	0	0	N/A
<i>Ice</i>	2 (4.6%)	1	1	0	N/A
<i>Water</i>	0	0	0	0	N/A
<i>Excercise/cholinergic</i>	0	0	0	0	N/A

**Supplementary Table 1.** Physical challenge tests stratified by anti-TPO groups. Comparison of anti-TPO IgE groups. **Group 1:** patients with anti-TPO IgE during the clinical control period and significantly increased levels during an exacerbation (n=18). **Group 2:** patients with anti-TPO IgE during the clinical control period with no increase during an exacerbation (n= 12) **Group 3:** patients with anti-TPO IgE only during an exacerbation (n= 13). N/A, not applicable.

**Supplementary table 2.**

NSAID challenge	Positive challenge	(+) Anti-TPO IgE (n 43)	Group 1 (n 18)	Group 2 (n 12)	Group 3 (n 13)	P
Any NSAID (total 46)	14	10 (23.2%)	4	3	3	0.14
Ibuprofen (20)	8	6 (11.6%)	2	2	2	0.15
ASA (10)	5	3 (6.9%)	1	1	1	0.14
Meloxicam (10)	1	1 (2.3%)	1	0	0	N/A
Acetaminophen (6)	0	0	0	0	0	N/A

**Supplementary Table 2.** NSAID challenge tests stratified by anti-TPO groups. *P* value for anti-TPO IgE groups. **Group 1:** patients with anti-TPO IgE during the clinical control period and significantly increased levels during an exacerbation (n=18). **Group 2:** patients with anti-TPO IgE during the clinical control period with no increase during an exacerbation (n=12) **Group 3:** patients with anti-TPO IgE only during an exacerbation (n=13). N/A, not applicable. ASA, acetylsalicylic acid.